Are you Dr. Brand?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 2 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3 Electronics Ave
Ste 201
Danvers, MA 01923Phone+1 978-750-0300Fax+1 978-279-1324
Summary
- Dr. Stephen Brand, MD is a gastroenterologist in Danvers, Massachusetts. He is currently licensed to practice medicine in Massachusetts, Connecticut, and Maine. He is affiliated with Encompass Health Rehabilitation Hospital of Western Massachusetts.
Education & Training
University of Western Australia Faculty of MedicineClass of 1975
Certifications & Licensure
MA State Medical License 1990 - 2026
ME State Medical License 2013 - 2026
NH State Medical License 2012 - 2026
RI State Medical License 2012 - 2026
CT State Medical License 2015 - 2025
Publications & Presentations
PubMed
- 121 citationsCombination Therapy With Epidermal Growth Factor and Gastrin Increases β-Cell Mass and Reverses Hyperglycemia in Diabetic NOD MiceWilma L. Suarez-Pinzon, Yanhua Yan, Robert F. Power, Stephen J. Brand, Alex Rabinovitch
Diabetes. 2005-09-01 - 144 citationsCombination Therapy with Epidermal Growth Factor and Gastrin Induces Neogenesis of Human Islet β-Cells from Pancreatic Duct Cells and an Increase in Functional β-Cell ...Wilma L. Suarez-Pinzon, Jonathan R. T. Lakey, Stephen J. Brand, Alex Rabinovitch
The Journal of Clinical Endocrinology and Metabolism. 2005-06-01 - 82 citationsPharmacological treatment of chronic diabetes by stimulating pancreatic beta-cell regeneration with systemic co-administration of EGF and gastrin.Stephen J. Brand, Sven Tågerud, Philip Lambert, Sheila G. Magil, Krystyna Tatarkiewicz
Pharmacology & Toxicology. 2002-12-01
Press Mentions
Mycovia Pharmaceuticals Announces Positive Topline Results from Its Third Phase 3 Clinical Trial (ultraVIOLET) of Oteseconazole for the Treatment of Recurrent Vulvovaginal CandidiasisJanuary 6th, 2021- Mycovia Pharmaceuticals Announces Positive Topline Results from Phase 3 VIOLET Studies of Oteseconazole in Patients with Recurrent Vulvovaginal CandidiasisDecember 9th, 2020
- Mycovia Pharmaceuticals Announces Peer-Reviewed Publication of Positive Study Results of Oteseconazole for the Treatment of Acute Vulvovaginal CandidiasisAugust 26th, 2020
- Join now to see all
Grant Support
- Gut Peptide Expression In The Endocrine PancreasNational Institute Of Diabetes And Digestive And Kidney Diseases1991–1993
- Physiological Regulation Of Gastrin Gene ExpressionNational Institute Of Diabetes And Digestive And Kidney Diseases1988–1992
- Gut Pepitde Expression In The Endocrine PancreasNational Institute Of Diabetes And Digestive And Kidney Diseases1990
